신생항원 표적치료 시장 : 치료법, 치료 접근, 투여 경로, 연령층, 대상 질환, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Neoantigen Targeted Therapies Market is projected to grow by USD 15.61 billion at a CAGR of 16.66% by 2032.

Neoantigen targeted therapies are reshaping precision oncology by focusing on tumor-specific mutations that are generally absent from healthy tissue. This approach supports highly individualized cancer vaccines, adoptive T-cell therapies, T-cell receptor programs, and combination regimens designed to direct immune activity toward patient-specific or shared tumor antigens.

The field is gaining momentum because next-generation sequencing, HLA typing, immunopeptidomics, and advanced bioinformatics can now identify actionable neoantigen candidates with greater speed and confidence. Clinical development remains complex, but the scientific rationale is strong: neoantigens can improve tumor specificity, support immune memory, and provide a differentiated path beyond conventional chemotherapy and broadly targeted biologics.

Transformative Shifts in the Neoantigen Therapy Landscape

The neoantigen targeted therapies landscape is shifting from exploratory immuno-oncology research toward scalable translational platforms. Improvements in whole-exome sequencing, RNA sequencing, single-cell analysis, and tumor microenvironment profiling are enabling developers to select more clinically relevant epitopes and design personalized therapies within commercially meaningful timelines.

Another major shift is the movement from single-modality development to rational combinations. Neoantigen vaccines and engineered cellular therapies are increasingly evaluated with immune checkpoint inhibitors, cytokine modulation, lymphodepletion strategies, or tumor microenvironment interventions. This reflects a growing recognition that antigen identification alone is not sufficient; durable response depends on antigen presentation, T-cell fitness, immune infiltration, and resistance management.

Cumulative Impact of Artificial Intelligence in Neoantigen Discovery

Artificial intelligence is becoming central to neoantigen discovery, prioritization, and manufacturing design. AI-enabled pipelines can integrate tumor DNA and RNA sequencing, HLA binding predictions, clonality assessment, antigen processing signals, and immunogenicity models to reduce the number of low-value candidates entering expensive validation workflows.

The cumulative impact of AI is also visible in clinical operations. Predictive analytics can support patient selection, trial stratification, toxicity monitoring, and adaptive protocol design. While AI models require rigorous validation across diverse HLA backgrounds and tumor types, they are accelerating the transition from data-heavy discovery to decision-ready therapeutic development.

Key Regional Insights for Neoantigen Targeted Therapies

North America remains a leading region for neoantigen targeted therapies due to its concentration of oncology biotechnology companies, academic cancer centers, contract development partners, and venture financing. The United States anchors this ecosystem through FDA-regulated clinical trial activity, broad sequencing adoption in oncology care, and strong translational research networks, while Canada contributes through cancer genomics, immunotherapy research, and publicly supported health innovation programs.

Europe benefits from established biopharmaceutical infrastructure, centralized regulatory engagement through the European Medicines Agency, and strong national oncology research systems across Germany, France, Italy, Spain, and the United Kingdom. The European Union's emphasis on health data governance and cross-border research can support multi-country trials, although reimbursement diversity, advanced therapy manufacturing capacity, and national health technology assessment requirements remain key considerations.

Asia-Pacific is expanding as China, Japan, South Korea, Australia, India, and ASEAN markets invest in precision medicine, clinical trial capacity, cancer genomics, and cell and gene therapy infrastructure. Latin America, led by Brazil and Mexico, offers growing oncology demand and improving clinical research participation, but access to advanced molecular diagnostics remains uneven across public and private care settings. The Middle East, especially GCC countries, is investing in genomics, specialty care, and tertiary oncology centers, while Africa represents an emerging opportunity where partnerships, pathology modernization, sequencing infrastructure, and equitable access models will determine long-term adoption.

Key Group Insights Across Global Innovation Blocs

Among major economic and geopolitical groups, the G7 holds a strong position in neoantigen targeted therapies because members combine advanced clinical trial systems, major biomedical research funding, high oncology care capacity, and deep regulatory experience. NATO countries overlap significantly with leading biomedical innovation hubs, supporting collaborative research, resilient supply chains, cold-chain logistics, and standardized approaches to advanced therapy handling.

The European Union is strategically important because it links scientific scale with harmonized regulatory pathways, clinical research networks, and data protection standards, creating a structured environment for multi-country oncology development. BRICS economies, particularly China, India, and Brazil, are increasingly relevant due to large patient populations, expanding sequencing capacity, and growing biomanufacturing capabilities, although regulatory maturity, reimbursement pathways, and access to high-complexity diagnostics vary by country.

ASEAN is becoming more attractive for clinical partnerships as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines improve oncology infrastructure, digital health adoption, and regional research connectivity. The GCC is also gaining importance through national genomics initiatives, investment in cancer centers, and demand for high-value precision oncology, creating opportunities for diagnostic-enabled therapy partnerships and specialized treatment pathways.

Key Country Insights in Neoantigen Targeted Therapy Adoption

The United States leads global commercialization potential for neoantigen targeted therapies through its advanced oncology trial ecosystem, strong venture capital base, mature regulatory framework for advanced therapies, and established reimbursement channels for high-value precision medicine. Canada complements this with cancer genomics research and publicly funded clinical networks. Mexico and Brazil are important Latin American markets where rising cancer burden and expanding private healthcare capacity support future adoption, provided molecular diagnostics, biopsy logistics, and specialized oncology access become more consistent.

In Europe, the United Kingdom, Germany, and France are prominent due to established oncology research centers, biopharma investment, genomic medicine programs, and strong clinical trial activity. Italy and Spain contribute meaningful patient recruitment capacity and specialist oncology networks, while Russia maintains scientific capabilities but faces operational and geopolitical constraints that can complicate international collaboration, technology transfer, and trial execution.

Across Asia-Pacific, China is a major force because of scale, domestic biotech growth, and investment in cell therapy, genomics, and oncology innovation. Japan and South Korea offer sophisticated regulatory systems, advanced hospitals, and strong biomanufacturing capabilities. India is increasingly relevant due to its large cancer population, expanding genomics sector, and cost-efficient clinical research environment. Australia has become a preferred early-phase oncology trial destination supported by high-quality sites, R&D incentives, experienced investigators, and strong translational research capacity.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated discovery platforms that combine tumor sequencing, HLA typing, transcriptomics, immunopeptidomics, and validated AI models. Competitive advantage will come from the ability to identify clinically relevant neoantigens quickly, manufacture individualized products reliably, and prove immune activation with robust biomarker evidence.

Organizations should also build combination strategies early, particularly with checkpoint inhibitors and tumor microenvironment modulators, while designing trials around measurable residual disease, adjuvant settings, and tumor types with high mutational burden. Strategic partnerships with sequencing providers, academic cancer centers, CDMOs, and real-world data networks can reduce execution risk and improve scalability.

Commercial planning should begin before pivotal trials. Developers need clear evidence packages for payers, manufacturing cost controls, decentralized sample logistics, and region-specific access models. Because personalized therapies challenge traditional reimbursement, outcomes-based contracting and diagnostic-linked value demonstration should be evaluated early.

Research Methodology

Research methodology is developed using a structured secondary-research approach. The analysis synthesizes information from regulatory agencies, peer-reviewed oncology literature, clinical trial registries, government health programs, academic cancer center publications, and recognized scientific organizations.

Insights are evaluated for clinical relevance, technological maturity, regulatory feasibility, geographic applicability, and commercial scalability. Particular attention is given to verified developments in next-generation sequencing, personalized cancer vaccines, adoptive T-cell therapies, AI-enabled antigen prediction, biomanufacturing, and immuno-oncology combinations. The methodology emphasizes triangulation across multiple credible sources rather than reliance on a single dataset.

Conclusion

Neoantigen targeted therapies represent one of the most precise frontiers in cancer immunotherapy. The sector is advancing because sequencing, computational biology, AI, and advanced manufacturing are converging to make personalized and highly specific treatment strategies more feasible.

The next phase of leadership will depend on evidence quality, speed of manufacturing, biomarker-defined patient selection, and the ability to demonstrate durable clinical benefit. Organizations that integrate scientific rigor with scalable operations and regional access planning will be best positioned to capture long-term value in this evolving precision oncology field.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neoantigen Targeted Therapies Market, by Therapy Modality

• 7.1. Adoptive Cell Therapy
  • 7.1.1. CAR-T Cell Therapy
  • 7.1.2. T Cell Receptor (TCR) Therapy
  • 7.1.3. Tumor-infiltrating lymphocytes (TIL)
• 7.2. Personalized Neoantigen Vaccines
  • 7.2.1. Dendritic Cell (DC) Vaccines
  • 7.2.2. DNA/ RNA-based Vaccines
  • 7.2.3. Peptide (SLP) Vaccines

8. Neoantigen Targeted Therapies Market, by Treatment Approach

• 8.1. Combination Therapy
• 8.2. Monotherapy

9. Neoantigen Targeted Therapies Market, by Route of Administration

• 9.1. Oral
• 9.2. Parenteral
  • 9.2.1. Intramuscular
  • 9.2.2. Intravenous
  • 9.2.3. Subcutaneous

10. Neoantigen Targeted Therapies Market, by Age Group

• 10.1. Adult
• 10.2. Geriatric
• 10.3. Pediatric

11. Neoantigen Targeted Therapies Market, by Target Disease Indication

• 11.1. Bone Cancer
• 11.2. Colorectal Cancer
• 11.3. Gynecological Cancer
• 11.4. Non-Small Cell Lung Cancer
• 11.5. Renal Cell Carcinoma

12. Neoantigen Targeted Therapies Market, by End-User

• 12.1. Academic & Government Research Institutes
• 12.2. Hospitals & Clinics
• 12.3. Specialty Clinics

13. Neoantigen Targeted Therapies Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Neoantigen Targeted Therapies Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Neoantigen Targeted Therapies Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Achilles Therapeutics Limited
• 17.2. Agenus Inc.
• 17.3. AstraZeneca plc
• 17.4. BioNTech SE
• 17.5. Bristol-Myers Squibb Company
• 17.6. CureVac N.V.
• 17.7. Eli Lilly and Company
• 17.8. EpiVax, Inc.
• 17.9. F. Hoffmann-La Roche AG
• 17.10. Genentech, Inc.
• 17.11. Genocea Biosciences, Inc.
• 17.12. Gilead Sciences, Inc.
• 17.13. GlaxoSmithKline plc
• 17.14. Gritstone bio, Inc.
• 17.15. Immatics N.V.
• 17.16. Immunomic Therapeutics, Inc.
• 17.17. IOVANCE Biotherapeutics, Inc.
• 17.18. Medigene AG
• 17.19. Merck & Co., Inc.
• 17.20. Moderna, Inc.
• 17.21. Neon Therapeutics, Inc.
• 17.22. Nykode Therapeutics
• 17.23. Pfizer Inc.
• 17.24. Precision Biologics
• 17.25. Valo Therapeutics Ltd